N Engl J Med (2015) 373(1):1122
Gastrointestinal AE with cagrisema were more than with semagutide or cagrilintide monotherapy, however the SAE and AE leading to medication discontinuation were minimal and similar between the groups [87, 90] A programme of phase 3 clinical trials (REDEFINE) assessing the safety and efficacy of cagrisema in people with obesity (NCT05567796, NCT05394519, NCT05813925) is currently ongoing
The testing includes accelerated stability studies (exposure to elevated temperatures to predict long-term behavior) and real-time stability studies (actual storage over the full shelf-life period)
Oral GLP-1 receptor agonists are also in the development phase, with preliminary data showing efficacy similar to that of Semaglutide
By offering convenient, nutritious options, Seattle Suttons Healthy Eating helps reduce the risks of complications associated with diabetes and obesity, ensuring that diet remains a key pillar of effective treatment